ReviewBriefings in bioinformatics2026
Structure-informed machine learning for drug discovery: a task-centric perspective.
Review in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- MSCA-PLA: multi-scale cross-attention with differentiable pooling for protein-ligand binding affinity prediction.Molecular diversity · 2026Article
- Structure-aware artificial intelligence for next-generation drug discovery: from protein-ligand modeling to generative biomolecular design.Briefings in bioinformatics · 2026Review
- Reproducibility, validation, and failure modes across classical and AI-driven molecular docking.Journal of computer-aided molecular design · 2026Review
- Opening the black box: insights into ubiquitin-mediated control of innate antiviral immunity and AI-enhanced therapeutics.Frontiers in immunology · 2026Review
- EnzyDiff: Sequence-based classification of mutation-induced enzyme activity direction using latent diffusion denoising.Science progressArticle
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
Advances in protein structure prediction have transformed the landscape of structure-based drug discovery, enabling deep learning models to incorporate spatial constraints into the design of target-specific ligands. This review provides a comprehensive synthesis of structure-aware molecular modeling from a task-centric perspective, focusing on binding pocket identification, interaction prediction, pose estimation, and complex modeling. We highlight the technological evolution from traditional docking and scoring frameworks toward geometry-informed deep learning architectures that encode protein structures via surface geometry, equivariant representations, and multi-modal embeddings. Special attention is given to recent progress in structure-conditioned molecular generation. We classify generative approaches into four core strategies: sequence-based generation with 3D conditioning, fragment-based linking and growing, graph-based generation under structural constraints, and 3D coordinate-based generation including diffusion models. Each paradigm balances chemical validity, spatial fidelity, and computational tractability in distinct ways, with diffusion-based and point cloud models emerging as powerful tools for synthesizing pocket-complementary molecules in full 3D space. We also discuss the emergence of co-folding models, which unify protein folding and ligand binding into a single predictive framework, bridging the gap between sequence-level learning and structural resolution. Finally, we examine the key challenges of data scarcity, generalization, and multi-objective control, and outline future directions toward scalable, interpretable, and physically plausible generation pipelines. By tracing how structural knowledge is reshaping AI-driven drug design, this review aims to provide both a conceptual roadmap and practical insight into next-generation molecular modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.